ENLV logo

Enlivex Therapeutics (ENLV)

Profile

Full Name

Enlivex Therapeutics Ltd.

Ticker Symbol

ENLV

Exchange

NASDAQ

Country

Israel

IPO

July 31, 2014

Indexes

Not included

Employees

71

Key Details

Price

$0.92(+3.84%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$0.73(+53.21% YoY)

PE ratio

-

Next earnings date

Aug 29, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Apr 3, 25 D. Boral Capital
Buy
Mar 24, 25 HC Wainwright & Co.
Buy
Mar 3, 25 D. Boral Capital
Buy
Feb 7, 25 D. Boral Capital
Buy
Dec 11, 24 D. Boral Capital
Buy
Dec 3, 24 D. Boral Capital
Buy
Nov 14, 24 D. Boral Capital
Buy
Sep 27, 24 HC Wainwright & Co.
Buy
Sep 26, 24 EF Hutton
Buy
Sep 24, 24 EF Hutton
Buy

Institutional Ownership

  • What is the ticker symbol for Enlivex Therapeutics?
  • Does Enlivex Therapeutics pay dividends?
  • What sector is Enlivex Therapeutics in?
  • What industry is Enlivex Therapeutics in?
  • What country is Enlivex Therapeutics based in?
  • When did Enlivex Therapeutics go public?
  • Is Enlivex Therapeutics in the S&P 500?
  • Is Enlivex Therapeutics in the NASDAQ 100?
  • Is Enlivex Therapeutics in the Dow Jones?
  • When was Enlivex Therapeutics's last earnings report?
  • When does Enlivex Therapeutics report earnings?
  • Should I buy Enlivex Therapeutics stock now?

What is the ticker symbol for Enlivex Therapeutics?

The ticker symbol for Enlivex Therapeutics is NASDAQ:ENLV

Does Enlivex Therapeutics pay dividends?

No, Enlivex Therapeutics does not pay dividends

What sector is Enlivex Therapeutics in?

Enlivex Therapeutics is in the Healthcare sector

What industry is Enlivex Therapeutics in?

Enlivex Therapeutics is in the Biotechnology industry

What country is Enlivex Therapeutics based in?

Enlivex Therapeutics is headquartered in Israel

When did Enlivex Therapeutics go public?

Enlivex Therapeutics's initial public offering (IPO) was on July 31, 2014

Is Enlivex Therapeutics in the S&P 500?

No, Enlivex Therapeutics is not included in the S&P 500 index

Is Enlivex Therapeutics in the NASDAQ 100?

No, Enlivex Therapeutics is not included in the NASDAQ 100 index

Is Enlivex Therapeutics in the Dow Jones?

No, Enlivex Therapeutics is not included in the Dow Jones index

When was Enlivex Therapeutics's last earnings report?

Enlivex Therapeutics's most recent earnings report was on Aug 30, 2024

When does Enlivex Therapeutics report earnings?

The next expected earnings date for Enlivex Therapeutics is Aug 29, 2025

Should I buy Enlivex Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page